Melanoma & Skin Cancer

Sunandana Chandra, MD, MS, Anna C. Pavlick, DO, MSc, MBA, BSN, and Nikhil Khushalani, MD, discuss the importance of multidisciplinary care in CSCC and patient counseling regarding available therapies.

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.

Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

The FDA has granted full approval to cemiplimab-rwlc for the treatment of patients with metastatic basal cell carcinoma who previously received a hedgehog inhibitor (HHI) or for whom a HHI is not appropriate.

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

The combination of darovasertib and crizotinib demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma.

Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.

Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.